



05 August 2025

Sydney, Australia

Notice of Change of Interests of Substantial Securityholder ("Notice")

Nyrada Inc (ASX: NYR), a clinical stage drug discovery and development company specialising in innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depository Interests ("CDIs"), a Notice of Change of Interests of Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder: Mr Mark Azzi

Date of change in the interests of the Substantial Holder: 01 August 2025

Previous and present voting power of Substantial Holder (through CHES Depository Nominees Pty Ltd):

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
34,947,597	16.57%	35,618,250	14.92%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
Mr Mark Azzi	Mr Mark Azzi	35,018,250	14.67%
Mr Mark Azzi	Mr Mark Azzi	400,000	0.17%
Mr Mark Azzi (2)	Mr Mark Azzi	200,000	0.08%

(1) Based on 238,655,370 CDIs on issue post allotment as outlined in ASX announcements released on 4 August 2025, comprising 211,455,370 CDIs currently on issue and 27,200,000 to be issued on 11 and 20 August 2025 under Capital Raising.

(2) 200,000 CDIs expected to be issued to Mr. Azzi on 11 August 2025 pursuant to a Subscription Agreement, a copy of which is attached as Annexure A.



NYR has provided a copy of this Notice to Mr Mark Azzi who has confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) (**Act**), including the number of equity securities or CDIs disclosed in the Notice, being 35,618,250 CDIs, and that these equity securities represent all equity securities held, and to be held under legal agreement, by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.

– ENDS –

About Nyrada Inc

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, CEO on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Account Number	[REDACTED]
Account Name and Designation	MR MARK AZZI
Offer Name	NYRADA INC
Firm Commitment (\$)	\$60,000.00
Settlement Required By	8:00AM (AEST) Friday, 8 August 2025

Dear Mark,

Canary Capital Pty Ltd is pleased to confirm your acceptance of the terms outlined in the previous offer letter sent to you.

Your cleared funds of \$60,000.00 are due no later than 8:00AM (AEST) Friday, 8 August 2025.

Settlement is via Direct Deposit

BANK	NAB
Account Name	Nyrada Inc
BSB	[REDACTED]
Account Number	[REDACTED]
Reference	[REDACTED]

If you have any queries, please contact your advisor Paul Hart on phart@canarycapital.com.au or corporate@canarycapital.com.au.

Kind Regards,
Srila Gott

M [REDACTED]
E corporate@canarycapital.com.au
Visit our website at www.canarycapital.com.au

Exempt Offering

This is not a public offer and has been prepared only for issue to, and use by, prospective investors who have been qualified as 'Excluded Investors' as defined in section 708 (8), 708 (10) & 708 (11) of the Corporations Act 2001 (Cth) (Corporations Act) and to any person in respect of whom the Offer does not require disclosure under Chapter 6D.2 of the Corporations Act. If you are not an Excluded Investor or do not meet other suitability requirements described in the Corporations Act, the Company will not accept your subscription.

For personal use only

Jurisdictional Disclaimer

This Term Sheet is not an offer of securities, and does not apply in any jurisdiction where, or to any person to whom, it would not be lawful to issue securities. If you access this Term Sheet or our website from locations outside Australia, you do so at your own initiative and are responsible for compliance with local fundraising laws.

No action has been taken to register or qualify the securities of companies published in this publication or our website or otherwise to permit a public offering of the securities on offer in any jurisdiction outside Australia.

Further, this publication does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities in the United States or in relation to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended ("the U.S. Securities Act")).

General Advice Warning

Please note that any advice given by Canary Capital Pty Ltd (Canary Capital) as a corporate authorised representative (CAR number 1254859) of BR Securities Australia Pty Ltd (ABN 92 168 734 530) which holds AFSL 456663 is GENERAL advice, as the information or advice given does not take into account your particular objectives, financial situation or needs. Before acting on the advice, you should consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument. Canary Capital Pty Ltd | ABN 18 618 657 640 | www.canarycapital.com.au. Our Financial Services Guide (FSG) is available on the Canary Capital website <https://canarycapital.com.au/financial-services-guide/>

Disclaimers

Canary Capital does not warrant the accuracy of any information it sources from others. Assessment of risk can be subjective. Historical information may not translate into future performance. Portfolios of investments need to be well diversified and the risk appropriate for the investor. Canary Capital does not stand behind the capital value or performance of any investment. To the fullest extent permitted by the law, Canary Capital disclaims any liability for any loss or damage arising from the use of, or the reliance on, any information within the advice whether or not caused by any negligent act or omission of Canary Capital. Overseas investors acknowledge that Canary Capital has not solicited their business. **Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value of less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.**

Disclosures

Paul Hart and Arun Sengupta are directors and authorised representatives of Canary Capital. They certify that any advice given by them, or any other authorised representative of Canary Capital reflects their honest view of a company. Directors and authorised representatives of Canary Capital may own securities in companies they recommend, which will be declared if they ever give advice. Authorised representatives receive a share of the brokerage and origination fees earned by Canary Capital in relation to companies they recommend, so they rely on their skills at selecting good investment opportunities for clients of Canary Capital. Canary Capital, its directors and associates and employees receive fees and share options from companies to which Canary Capital is mandated to provide corporate advisory services. The companies currently mandated are AKA, NYR, REZ, M2M, ILT, DekkoSecure and Lavablue.

Cyber Security & Fraud

Hackers have impersonated any number of firms and companies (especially financial institutions), and requested payment via email using their own account details. It is important you take the extra step to verify any bank account details you receive an email from Canary Capital, by speaking to us before transferring money. It is recommended that you use a search engine to locate our website, verify our phone number, and call us. Please do not reply to any emails for payment before verifying its authenticity with us. This is particularly relevant should you receive an email purporting to be from Canary Capital in which we notify you of a change in our bank account details, or bank account details into which you must pay funds. Canary Capital is not, and will not be, liable in the event that you transfer funds into an incorrect account.